FibroGen is dedicated to creating innovative, first-in-class medicines for the treatment of chronic and life-threatening or debilitating conditions such as anemia in chronic kidney disease (CKD), anemia in myelodysplastic syndromes (MDS) and chemotherapy induced anemia (CIA), idiopathic pulmonary fibrosis (IPF), pancreatic cancer, Duchenne muscular dystrophy (DMD), and COVID-19. The products we develop represent more than isolated opportunities or single indications — we see our products as representing broader platforms that enable us to continue to investigate discrete pathways and mediators that are central to multiple diseases.
Pipeline
HIF Platform
HIF Platform
- Preclinical Preclin
- Phase Ph1 Phase 1
- Ph2 Phase 2
- Ph3 Phase 3
- Approved Approved
HIF Platform
HIF Platform
- Preclinical Preclin
- Phase Ph1 Phase 1
- Ph2 Phase 2
- Ph3 Phase 3
- Approved Approved
- Preclinical Preclin
- Phase Ph1 Phase 1
- Ph2 Phase 2
- Ph3 Phase 3
- Approved Approved
United States
- Ph2
Fibrotic Disease Platform
Fibrotic Disease Platform
- Preclinical Preclin
- Phase Ph1 Phase 1
- Ph2 Phase 2
- Ph3 Phase 3
- Approved Approved
Pancreatic Cancer
- Ph3
Idiopathic Pulmonary Fibrosis
- Ph3
Duchenne Muscular Dystrophy
- Ph3
COVID-19
- Ph2
- Partnered
- Wholly-Owned
1 IND Approved for Phase 3 Study
2 CTA Approved for Phase 2/3 Study
Roxadustat
Roxadustat is a first-in-class, oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) currently being evaluated for the treatment of anemia in patients with chronic kidney disease (CKD), anemia associated with myelodysplastic syndromes (MDS), and chemotherapy-induced anemia (CIA).
Pamrevlumab
Pamrevlumab, our proprietary fully human antibody, represents a potential treatment for a broad array of fibrotic and proliferative disorders that affect organ systems throughout the body.
